Sciton announced the launch of Halo, a hybrid fractional laser that applies tunable non-ablative and ablative wavelengths in a single pass to maximize results and reduce downtime. Sciton will be premiering Halo at the 72^nd Annual Meeting of the American Academy of Dermatology. "Halo is not an incremental product. It is the culmination of an extensive four-year investigation involving new understanding of laser tissue physics combined with state-of-the-art implementation of all new technology," said Dan Negus, President of Sciton. "This product has some very exciting innovations that will excite a lot of users. Launching Halo further demonstrates Sciton's long commitment to excellence and innovation across all types of resurfacing."

Halo delivers both ablative and non-ablative wavelengths to the same microscopic treatment zone: 1470nm for coagulation and 2940nm for ablation. The 1470nm wavelength is used for delivering between 100 and 700 microns of coagulation to the epidermis and dermis, where solar damage exists. The 2940 nm wavelength is used to deliver from 0 to 100 microns of ablation to the epidermis of the skin. This gives Halo the unique ability to provide separate treatments for the epidermis, which heals quickly, and dermis, which remodels more slowly over time. The operator may choose one of three coverage-base treatment levels, and Halo calculates the exact amount of energy necessary to complete a safe and effective treatment. Intelligent energy delivery, combined with Dynamic Thermal Optimization, ensures precise and even treatments, each and every time. The benefits of a Halo treatment include both epidermal and deeper dermal pigmentation and tone and texture in the skin.

"Sciton's Halo is the first real innovation in lasers in the last decade," says Plastic Surgeon Jason Pozner, MD, FACS. "Hybrid Fractional Lasers are the next logical evolution in fractional resurfacing. With Halo, I can achieve results which I would have only expected from an ablative fractional laser, but get downtimes that I would normally see with a non-ablative fractional laser. It really is the best of both worlds."

Halo is available on the JOULE™ platform, which offers multiple modules to treat a wide range of indications. To learn more about Halo, visit www.HaloBySciton.com.